AI-Powered Drug Developer Eglen Pharma Wins Award at Qianwan New Area Innovation Roadshow

On August 9, the "AI Empowering the Life and Health Industry" special session of the "New Drug Startups in Qianwan" series roadshow successfully concluded in Ningbo Qianwan New Area. Twenty-one cutting-edge companies competed on key dimensions such as breakthrough innovations in core AI technology platforms, critical milestones in the R&D process, enormous potential in the trillion-level market, design of sustainable business models, and the professional strengths of their management teams.At the "AI-Innovative Drugs" themed session, Evergreen Therapeutics won the second prize for its outstanding achievements in AI-empowered clinical research in China.

The event was attended by senior judges and investors from various government departments such as the Economic and Information Bureau and the Organization Department of Qianwan New Area, well-known investment institutions including Ningbo Angel Investment Guidance Fund, SoftBank China, Kangjun Investment, Qiming Venture Partners, leading industrial players, and top academic institutions. With their deep industry insights, they conducted highly in-depth and valuable precise questioning and discussions on project technology applications and commercialization.

This award is a high recognition of Evergreen Therapeutics' profound strength in AI clinical technology, and also an important manifestation of the company's continuous investment and forward-looking strategy in the field of innovative drug development.

As an international innovative pharmaceutical company driven by AI clinical technology, Evergreen Therapeutics is committed to developing first-in-class drugs for unmet needs, leveraging the deep integration of AI technology and drug research and development.Evergreen Therapeutics' Self-developed AI Platform Can Greatly Improve R&D Efficiency and Success RateThe platform covers six major functional modules: Mechanism of Action (MOA) and indication optimization, pathway analysis and mechanism elucidation, multi-omics integration and patient stratification, clinical trial protocol writing and generation, drug repurposing, and clinical trial prediction and optimization. It integrates data from clinical records, genetic databases, and Real-World Evidence (RWE). By systematically uncovering molecular mechanisms and validating therapeutic hypotheses, the AI platform accelerates drug discovery and development, enabling more precise target identification, deeper understanding of disease mechanisms, and optimized clinical trial design. This helps users make faster decisions and improve clinical trial outcomes. Currently, six self-developed pipelines of Evergreen Therapeutics have been approved to enter clinical trials in the United States, with over 60 patent applications filed, covering major pharmaceutical markets worldwide, including China, the U.S., Europe, and Japan.